Introduction
Neoplasia, in¯ammation, immune responsiveness, and wound repair involve communication among multiple growth factors and cytokines often secreted by stromal and hematopoietic cells (Leek et al., 1994) . Among the many promoters of growth and modulators of dierentiation are PDGF and IL-4. PDGF is a proliferative and chemotactic factor for mesenchymal cells (Aaronson, 1991; Heldin and Westermark, 1991) . Although PDGF plays a critical role in wound healing and developmental processes (Ataliotis and Mercola, 1997) , accumulating evidence suggests that its abnormal expression contributes to a variety of diseases including cancer (Aaronson, 1991; Betsholtz and Raines, 1997; Dirks and Bloemers, 1996; Heldin and Westermark, 1991) . The role of PDGF in glioma (Fleming et al., 1992) , ®brosarcoma (Fleming et al., 1992) , mesothelioma (Van der Meeren et al., 1993) and lung cancer (Vignaud et al., 1994) has been clearly documented. Among the PDGF isoforms, PDGF BB is the human homolog of the v-sis oncogene product Doolittle et al., 1983; Water®eld et al., 1983) . Jak1, Jak2 and Tyk2 (Vignais et al., 1996) , as well as Stat1, Stat3 (Sadowski et al., 1993; Silvennoinen et al., 1993) , Stat5 (Novak et al., 1996; Patel et al., 1996) and Stat6 (Patel et al., 1996) have been implicated among the many PDGFR downstream eector molecules (Claesson-Welsh, 1996) .
The pleiotropic cytokine IL-4 plays a central role in the regulation of in¯ammatory and cell-mediated immune responses (Paul, 1997) . In addition to proliferative and dierentiation eects (Conrad et al., 1987; Noelle et al., 1984) , IL-4 also increases IL-4R expression on lymphocytes (Ohara and Paul, 1988) . In ®broblasts, IL-4 modulates functional responses such as extracellular matrix production (Postlethwaite et al., 1992) and chemotaxis (Postlethwaite and Seyer, 1991) , rather than inducing pronounced proliferative eects (Postlethwaite et al., 1992) . IL-4R activation (Wang et al., 1992) results in tyrosine phosphorylation of many signaling molecules including Jak1, Jak3 (Johnston et al., 1994; Witthuhn et al., 1994) , IRS-1 (Wang et al., 1993b) , IRS-2/4PS (Wang et al., 1993a) , and Stat6 (Hou et al., 1994; Kotanides and Reich, 1993; Quelle et al., 1995; Schindler and Darnell, 1995) . In Stat6 de®cient mice, IL-4-induced proliferation of T cells as well as B cells after IgM stimulation was dramatically reduced (Kaplan et al., 1996; Shimoda et al., 1996; Takeda et al. 1996) . Th2 helper T cell dierentiation and immunoglobulin class switching were greatly diminished (Kaplan et al., 1996; Shimoda et al., 1996; Takeda et al., 1996) .
STAT signaling pathways participate in malignant events (Garcia and Jove, 1998; Nelson and LaRochelle, 1999) . c-Sis/PDGF BB, v-Abl (Danial et al., 1995) and p190 Bcr ± Abl (Ilaria and Van Etten, 1996) were found to induce Stat6 activation. Elucidation of the human Stat6 genomic structure and mapping to chromosome 12q13.3 ± q14.1 suggested that Stat6 may participate in the development of some solid tumors (Patel et al., 1998a) . We have recently shown that IL-4 aects speci®c PDGF-mediated biological responses (Patel et al., 1996) . In support of this hypothesis, mast cell secreted IL-4 has been shown to augment low dose PDGF-induced ®broblast proliferation after cell-cell contact (Trautmann et al., 1998) . In ®brotic diseases such as scleroderma, IL-4 and PDGF have been shown to be overexpressed (Gay et al., 1989; Needleman et al., 1991) . The role of Stat6 in PDGF and IL-4 signaling in mesenchymal cells, especially primary ®broblast explants has not been studied. Here, we established and characterized early passage ®broblasts from wild-type and Stat6 null mouse skin biopsies, to investigate the consequences of Stat6's deletion on PDGF-and IL-4-induced proliferation and transcriptional activation. 7/7 ®broblasts were treated with PDGF, whole cell lysates prepared, immunoprecipitated with anti-PDGFR serum, and immunoblotted with antiphosphotyrosine mab. As shown in Figure 1a , we detected a similar phosphotyrosine content in PDGFRs immunoprecipitated from either PDGFtreated wild-type or Stat6 7/7 ®broblasts. No tyrosine phosphorylated PDGFR was detected in untreated ®broblasts. Immunoblotting of PDGFR immunoprecipitates with anti-PDGFR serum revealed that PDGFR protein levels were similar in both fibroblast populations (Figure 1b) . Control serum immunoprecipitates showed no detectable PDGFR (Figure 1b) .
Results

PDGFR
IL-4R expression in lymphocytes has been shown to be regulated by IL-4 treatment (Ohara and Paul, 1988 ) and a heterologous IL-4R promoter/reporter has also been shown to be enhanced through Stat6 (Kotanides and Reich, 1996) . To test the role of Stat6 in ®broblast IL-4R modulation, we ®rst examined the competence of wild-type and Stat6 7/7 primary ®broblasts to respond to IL-4. Immunoprecipitation of IL-4R with anti-IL-4R serum followed by immunoblotting with anti-phosphotyrosine mab revealed similar amounts of tyrosine phosphorylated IL4Rs after IL-4 treatment in wild-type or Stat6 7/7 ®broblasts ( Figure 1c) . No tyrosine phosphorylated IL-4R was detected in untreated ®broblasts. Similar amounts of IL-4R protein were also demonstrated in these immunoprecipitates after immunoblotting with anti-IL-4R mab (Figure 1d) . Therefore, the loss of Stat6 did not eect PDGFR and IL-4R activation or basal receptor protein expression levels in Stat6 ®broblasts. Early passage ®broblasts were treated with PDGF, immunoprecipitated with anti-phosphotyrosine or control mab, and immunoblotted with antiphosphotyrosine mab. As shown in Figure 2a , both wild-type and Stat6 7/7 ®broblasts contained similar patterns and intensities of tyrosine phosphorylated substrates. No tyrosine phosphorylated substrates were detected in untreated ®broblasts.
As an additional measure of the ability of Stat6
®broblasts to signal through the PDGFR, we examined PI 3-kinase, a substrate implicated in critical PDGFR functional pathways (Kundra et al., 1994) and readily translocated into tyrosine phosphorylated complexes after activation. As shown in Figure 2b , immunoprecipitation with anti-phosphotyrosine mab, but not control mab, followed by anti-PI 3-kinase immunoblotting revealed the presence of an activated p85 species in both PDGF-treated wild-type and Stat6 7/7 ®broblasts.
Figure 1 PDGFR and IL-4R activation in ®broblasts derived from wild-type or Stat6 de®cient mice. Early passage ®broblasts from wild-type or Stat6 null mice were incubated in the absence or presence of PDGF BB (100 ng/ml) or IL-4 (500 ng/ml) for 10 min. Whole cell lysates were then immunoprecipitated with anti-PDGFR serum or anti-IL-4R antibody and subjected to SDS ± PAGE as indicated in Materials and methods. Resolved proteins were transferred to Immobilon P membranes and immunoblotted with anti-phosphotyrosine mab (anti-PY, a, c), anti-PDGFR serum (b) or anti-IL-4R mab (d). Bound primary antibody was detected by anti-mouse or anti-rabbit antibody conjugated to horseradish peroxidase followed by enhanced chemiluminescence. The position of the PDGFR or IL-4R is indicated PI 3-kinase activation was equivalent in either cell type and not observed in untreated ®broblasts. We conclude that Stat6 7/7 ®broblasts are not signi®cantly altered in response to PDGF as measured by PDGFR activation, gross tyrosine phosphorylation of PDGFR substrates, or PI 3-kinase activation.
We further investigated whether Stat6 was a PDGFR substrate in our early passage ®broblast populations. Whole cell lysates from PDGF BBstimulated ®broblasts were immunoprecipitated with anti-Stat6 serum, subjected to SDS ± PAGE, and the resolved proteins immunoblotted with anti-phosphotyrosine mab. As shown in Figure 3 , a 100 kDa tyrosine-phosphorylated species was revealed in PDGF BB-treated wild-type ®broblasts. No tyrosine phosphorylated species were detected in untreated wildtype ®broblasts, despite the fact that the immunoprecipitates of PDGF BB-treated or untreated wild-type ®broblasts contained similar amounts of Stat6 protein (Figure 3) . No Stat6 was detected in control serum immunoprecipitates. As expected, no Stat6 or Stat6 tyrosine phosphorylation was detected in Stat6
®broblasts. All of these results provide the ®rst evidence that PDGF induced tyrosine phosphorylation of Stat6 in early passage mouse ®broblasts and that this activity was lost in Stat6 7/7 ®broblasts.
Eect of Stat6 deletion on PDGF induction of STAT DNA binding activities
Stat1, 3 and 5 have also been shown to be activated by PDGF (Novak et al., 1996; Patel et al., 1996; Sadowski et al., 1993; Silvennoinen et al., 1993) . Therefore, we investigated the consequences of deleting Stat6 on the activation of these other STAT family members. Wildtype or Stat6 7/7 ®broblasts were treated with PDGF, whole cell extracts prepared, and assayed for the induction of Stat1, 3, 5 and 6 DNA binding activity by EMSA. As shown in Figure 4 , the extent of PDGFactivated [ 32 P]SIE binding and mobility of Stat1 ± Stat3 heterodimers (Zhong et al., 1994) To determine whether the loss of Ie DNA binding activity was directly attributable to the loss of Stat6 and not some other defect, we investigated whether PDGF-induced Ie DNA binding activity could be rescued by ectopic Stat6 expression. However, since cDNA transfection of early passage ®broblasts proved inecient, SV40 large T antigen immortalized fibroblast cell lines were established and transfected with Figure 2 PDGFR substrate tyrosine phosphorylation and PI-3 kinase activation in wild-type or Stat6 null ®broblasts. Wild-type or Stat6 null early passage ®broblasts were incubated in the absence or presence of PDGF BB (100 ng/ml) for 10 min. Whole cell lysates were then immunoprecipitated with anti-phosphotyrosine mab or control antibody MOPC-21 followed by SDS ± PAGE. Resolved proteins were transferred to Immobilon P membranes and immunoblotted with anti-phosphotyrosine mab (anti-PY, a) or PI-3 kinase antiserum (b). Bound primary antibody was detected by anti-mouse antibody or anti-rabbit antibody conjugated to horseradish peroxidase followed by enhanced chemiluminescence Figure 3 PDGF induction of Stat6 tyrosine phosphorylation in wild-type or Stat6 null ®broblasts. Early passage ®broblasts from wild-type or Stat6 null mice were incubated in the absence or presence of PDGF BB (100 ng/ml) for 20 min. Whole cell lysates were then immunoprecipitated with anti-Stat6 serum and subjected to SDS ± PAGE as indicated in Materials and methods. Resolved proteins were transferred to Immobilon P membranes and immunoblotted with anti-phosphotyrosine mab (anti-PY, a) or anti-Stat6 serum (b). Bound primary antibody was detected by anti-mouse antibody or anti-rabbit-antibody conjugated to horseradish peroxidase followed by enhanced chemiluminescence. (Figure 6a ). Addition of IL-4 to PDGF BB (5 ng/ml) increased the PDGF BB-induced response from 19-to 25-fold. The enhancement due MMTgpt ± Stat6 (b), or wild-type MMTgpt (c) transfectants were untreated or treated with 100 ng/ml PDGF BB, 500 ng/ml IL-4, or both 100 ng/ml PDGF BB and 500 ng/ml IL-4 for 20 min as indicated. Whole cell lysates from ®broblasts were then incubated with [ 32 P]Ie for 15 min and assayed by EMSA as described in Materials and methods. Gels were exposed for 24 h and visualized by autoradiography. A PDI 420oe scanning densitometer with QS30 software was used to quantitate the induction of Ie binding activity. The relative mobility of the induced Ie mobility shift is indicated to IL-4 in primary wild-type ®broblasts was most dramatic at PDGF BB concentrations below those required for maximal induction of DNA synthesis. Between 1 and 5 ng/ml PDGF BB, the presence of IL-4 eectively reduced the concentration of PDGF BB required to induce the same [ ®broblasts required SV40 immortalization that precluded [ 3 H]thymidine uptake studies due to high background isotope incorporation. As an alternative approach to verify our hypothesis we exploited NIH3T3 ®broblasts transfected with Stat6c, a naturally occurring Stat6 dominant negative variant previously cloned in our laboratory (Patel et al., 1998b) . As shown in Figure 6b, (Figure 6b ). These data provide further evidence that Stat6 plays a role in IL-4-enhanced PDGF-induced proliferation.
IL-6 and MCP-1 transcriptional regulation in wild-type and Stat6
7/7 ®broblasts PDGF or IL-4 treatment of ®broblasts has been shown to transcriptionally upregulate the proin¯ammatory cytokine, IL-6 (Doucet et al., 1998; Feghali et al., 1992; Paquet and Pierard, 1996) , as well as the chemokine, MCP-1 (Doucet et al., 1998; Hall et al., 1989) . Since Stat6 is a common transcription factor in both PDGF and IL-4 signaling pathways, we tested whether Stat6 might mediate IL-6 and MCP-1 induction. Total RNA was prepared from wild-type or Stat6 7/7 ®broblasts after growth factor or cytokine treatment. As shown in Figure 7 , IL-4 treatment of wild-type ®broblasts induced IL-6 mRNA (a major 1.4 kb and minor 2.4 kb species) about ®vefold at 6 and 12 h. A potent 13-fold increase in transcript was observed at 48 h. Strikingly, IL-4 treatment of Stat6 7/7 ®broblasts resulted in only a 1.5-fold induction of IL-6 mRNA. Even at 48 h, IL-6 transcript induction was quantitated at about fourfold. PDGF BB upregulation of IL-6 mRNA at 48 h was approximately 4.4-fold and 4.6-fold for wild-type and Stat6 7/7 ®broblasts respectively ( Figure 7) . Together, IL-4 and PDGF BB did not enhance IL-4's induction of the IL-6 transcript. As additional controls, PDGF BB's upregulation of VEGF (vascular endothelial cell growth factor) and c-myc transcripts was equivalent in wild-type or knockout ®broblasts (data not shown).
To con®rm these results, we also performed IL-6 two-site ELISA studies. Wild-type or Stat6 7/7 fibroblasts were treated with PDGF BB, IL-4, or both for 48 h and culture supernatants harvested. As shown in Table 1 , the two-site ELISA showed that IL-4 treatment resulted in about a sevenfold greater accumulation of IL-6 in the conditioned medium of wild-type ®broblasts than Stat6 7/7 ®broblasts. PDGF BB induced IL-6 production to a similar extent in both cell types, and little dierence was noted between PDGF-induced accumulation in the presence or absence of IL-4 (Table 1) .
To investigate the role of Stat6 in MCP-1 expression, total RNA was prepared and conditioned medium harvested from wild-type or Stat6 7/7 fibroblasts after PDGF BB and/or IL-4 addition. As shown in Figure 7 , IL-4 treatment of wild-type ®broblasts, but not Stat6 7/7 ®broblasts, resulted in about a 2.5-fold induction of MCP-1 mRNA at 6 h. In only wild-type ®broblasts, a potent tenfold increase in transcript was observed at 48 h and PDGF BB increased IL-4's induction twofold (Figure 7 ). In both cell types, PDGF BB upregulated MCP-1 transcript only marginally at 48 h. At 2 h, a time point selected for maximal MCP-1 induction by PDGF BB, MCP-1 transcript was induced equally well in both wild-type and Stat6 7/7 ®broblasts (data not shown). IL-4 did not aect PDGF BB's induction of MCP-1 at 2 h (data not shown).
A two-site ELISA demonstrated that the amount of MCP-1 that speci®cally accumulated in response to IL-4 at 48 h was much greater in wild-type ®broblasts (5.7+0.3 ng/ml) than Stat6 7/7 ®broblasts (1.7+0.1 ng/ ml). PDGF BB showed little of MCP-1 induction at 48 h. In concordance with our transcript data, IL-4 and PDGF BB together induced MCP-1 about twofold (to 13.5+1.2 ng/ml) in wild-type ®broblasts. All of these results suggest that Stat6 is required for IL-4, as well as IL-4 and PDGF BB enhanced induction of MCP-1 expression in early passage murine ®broblasts.
Discussion
We generated and characterized early passage fibroblasts from wild-type and Stat6 null mice to determine the eect of Stat6 gene ablation on PDGF and IL-4-mediated signaling, proliferation, and transcriptional activation. PDGF and IL-4 receptor expression as well as PDGF-induced gross substrate tyrosine phosphorylation, PI 3-kinase activation, and Stat1, 3 and 5 DNA binding activity remained unchanged. Concomitant with the loss of Stat6 induction in Stat6
®broblasts, IL-4-enhancement of PDGF-induced proliferation was markedly diminished, although PDGFmediated proliferation was not signi®cantly altered. Furthermore, IL-4 induction of IL-6 and MCP-1 was also greatly reduced. Rescue of Stat6 binding activity by transfection of a Stat6 expression construct attributed these eects directly to the Stat6 lesion. Therefore, Stat6 appears to play a unique role in PDGF proliferative events enhanced by IL-4, as well as IL-4's induction of IL-6 and MCP-1 in murine ®broblasts.
A recent study has demonstrated that IL-4R expression was induced after IL-4 treatment of lymphocytes (Ohara and Paul, 1988) . Stat6 has been proposed to regulate IL-4R expression, since a heterologous IL-4R promoter/luciferase reporter containing an endogenous Stat6 consensus binding sequence was activated by IL-4 in Stat6 overexpressing HeLa cells (Kotanides and Reich, 1996) . In Stat6
®broblasts, we observed that IL-4R basal expression and activation by IL-4 were not aected by the loss of Stat6. Furthermore, the kinetics of IL-4R induction between 0 and 6 h after IL-4 treatment was also unaected as assayed by immunoblotting (P Kriebel and WJ LaRochelle, unpublished observation). Clearly, transcriptional activation pathway(s) independent of Stat6 must regulate IL-4R expression in murine ®broblasts.
The observation that PDGF and IL-4 induced the transcriptional activation of the proin¯ammatory cytokine IL-6 and the chemokine, MCP-1 (Doucet et al., 1998; Feghali et al., 1992; Hall et al., 1989; Paquet and Pierard, 1996; Roth et al., 1992) prompted us to determine whether the common activation of Stat6 might explain these eects. Our data showed that Stat6 was required for potent induction of IL-6 and MCP-1 by IL-4, but not exclusively by PDGF. However, we cannot exclude the possibility that alternative PDGF signaling events such as Stat3 (Sadowski et al., 1993; Silvennoinen et al., 1993) , AP-1 (Barone and Courtneidge, 1995) and/or NF-kB (Freter et al., 1996; Olashaw et al., 1992) activation as well as IL-1 induction (Honda et al., 1992; Takemura et al., 1998) might compensate for the loss of Stat6 and explain PDGF-induced IL-6 or MCP-1 expression. In addition to IL-6 and MCP-1, we attempted to deduce other potential candidate genes for Stat6 transcriptional regulation in ®broblasts by identifying downstream transcriptional targets common to both PDGF and IL-4 pathways. In fact, inspection of PDGF and IL-4 eects on ®broblasts revealed that both regulate the transcription of genes encoding extracellular matrix proteins (Owen et al., 1982; Postlethwaite et al., 1992) . To date, we have been unable to observe a dierential eect in the expression of several extracellular matrix proteins in wild-type compared to Stat6 7/7 ®broblasts (P Kriebel and WJ LaRochelle, unpublished observation) although compensatory transcriptional activators cannot be excluded.
Since IL-6 has been shown to enhance the G 0 to G 1 transition in monocytes (Ikebuchi et al., 1987) , we investigated whether it might exert a similar eect in dermal ®broblasts. gp130 receptor activation was detected, but after IL-6 induction no signi®cant increase in phosphotyrosine content was found (P Kriebel and WJ LaRochelle unpublished observation). Therefore, IL-6 appeared not to function in an autocrine manner in dermal ®broblast cell culture. The possibility remains that IL-6 might aect ®broblast proliferation and dierentiation in vivo; for example, after complementation with the soluble IL-6R subunit found in serum (Honda et al., 1992) . Additionally, IL-6 and MCP-1 secreted from dermal ®broblasts are likely to function in a paracrine manner on adjacent cell types. In any case, regulation of stromal ®broblast IL-6 and MCP-1 induction provides further evidence for Stat6's contribution to inflammatory diseases including allergen-induced airway hyperresponsiveness (Kuperman et al., 1998). Stat6 7/7 ®broblasts may provide an excellent model system to elucidate the role of Stat6 in ®broblast transcriptional activation by approaches such as dierential display RT ± PCR or dierential analysis of cDNA expression arrays.
Materials and methods
Materials
Anti-Stat6 peptide sera used for immunoprecipitation and immunoblot analyses were raised against amino acid residues 689 ± 711 (NH 2 -VPQVYPPHSHSIPPYQGLSPEES-COOH) and 787 ± 804 (NH 2 -GEDIFPPLLPPTEQDLTK-COOH), respectively. The anti-PDGFR serum has been previously described (Jensen et al., 1992) . Anti-phosphotyrosine monoclonal antibody (mab) and anti-PI 3-kinase serum were purchased from Upstate Biotechnology Inc. (Lake Placid, NY, USA). Anti-IL-4R mab was purchased from Genzyme (Cambridge, MA, USA). Recombinant human PDGF BB and murine IL-4 were obtained from Peprotech (Rocky Hill, NJ, USA). Human Stat6 cDNA was cloned in our laboratory (Patel et al., 1996) and its coding sequence identical to that published by Hou et al. (1994) .
Early passage and SV40 immortalized wild-type and Stat6
7/7 ®broblasts Skin biopsies from wild-type or Stat6 7/7 mice (Kaplan et al., 1996) were collagenase digested overnight. Cells were collected by centrifugation after a low speed centrifugation that removed undigested debris. The cell pellets were washed and plated in TP medium (Dulbecco's modi®ed Eagle's medium with 10% fetal calf serum) containing insulin (5 mg/ ml), bFGF (5 ng/ml), and EGF (5 ng/ml). All studies were performed on early passage ®broblasts except where noted. The results presented in this study are representative of the wild-type or Stat6 7/7 ®broblast populations. For Stat6 reconstitution experiments, wild-type or Stat6 7/7 ®broblasts were ®rst immortalized with SV40 large T antigen (Peden et al., 1987) by calcium phosphate transfection (Wigler et al., 1977) . Immortalized wild-type or Stat6 7/7 ®broblasts were transfected with 10 mg of mouse metallothionein expression vector (MMTgpt) or vector containing human Stat6 cDNA (MMTgpt ± Stat6). Transfectants were selected for growth in hypoxanthine-aminopterin-thymidine (HAT) medium containing mycophenolic acid. Cells were weaned and then passaged in TP medium. For some experiments, NIH3T3 ®broblasts were transfected with pCEV27 ± Stat6c and selected with geneticin (750 mg/ml) as previously described (Patel et al., 1996) .
Tyrosine phosphorylation of signaling molecules
Wild-type or Stat6 7/7 ®broblasts were serum starved and stimulated with PDGF BB for 10 min to detect activated PDGFR and substrates. A 20 min PDGF BB treatment was used to detect Stat6 activation. Prior to harvesting, cells were washed once with PBS, 100 mM sodium orthovanadate. Whole cell lysates were prepared by solubilization in RIPA buer [50 mM Tris pH 7.4, 50 mM NaCl, 1.0% Triton X-100, 5 mM EDTA, 10 mM sodium pyrophosphate, 50 mM sodium uoride, 1 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl¯uoride, leupeptin (10 mg/ml), pepstatin (10 mg/ml) and aprotinin (1 mg/ml)], sonication, and incubation on ice for 30 min. Lysates were cleared by centrifugation at 14 000 r.p.m. for 10 min. Lysates containing equivalent amounts of total protein as determined by the method of Bradford were incubated with anti-Stat6 serum for 2 h. Next, 100 ml of a 1 : 1 slurry of protein A Sepharose CL4B was added for 1 h. Immunocomplexes were washed three times with RIPA buer. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS ± PAGE) sample buer containing 100 mM dithiothreitol was added, and the samples were fractionated on 8% SDS-polyacrylamide gels.
After electrophoretic transfer to Immobilon P membranes, ®lters were blocked in TTBS (20 mM Tris pH 7.4, 150 mM NaCl, 0.05% Tween 20), 3% nonfat milk. Membranes were then incubated with anti-Stat6 antiserum (1 : 1000) or antiphosphotyrosine (1 : 1000) for 1 ± 2 h in TTBS, 1% BSA, and washed four times with TTBS. Bound antibody was detected by incubation with anti-rabbit (1 : 10 000) or anti-mouse antibody (1 : 10 000) conjugated to horseradish peroxidase (Amersham, Arlington Heights, IL, USA) for 30 min and subsequently washing four times with TTBS. Enhanced chemiluminescence (Amersham) was performed according to the manufacturer's protocol.
Detection of IL-4R tyrosine phosphorylation in wild-type or Stat6 7/7 primary ®broblasts was performed in an identical manner with the following exceptions. Cells were triggered with 500 ng/ml murine IL-4 for 10 min and immunoprecipitated with 5 ml of anti-IL-4R antibody or control antibody. For detection of IL-4R protein, immunoprecipitates were immunoblotted with (1 : 400) anti-IL-4R mab. Tyrosine phosphorylated substrates including PI 3-kinase were immunoprecipitated with 5 mg of anti-phosphotyrosine mab and immunoblotted with anti-phosphotyrosine as described. For detection of PI 3-kinase activation, anti-phosphotyrosine immunoprecipitates were immunoblotted with (1 : 400) anti-PI 3-kinase serum.
Electrophoretic mobility shift analysis DNA oligonucleotide probes used in the electrophoretic mobility shift assay (EMSA) were annealed, labeled, puri®ed, and whole cell extracts were prepared for EMSA as described (Patel et al., 1996) . Brie¯y, wild-type or Stat6 7/7 ®broblasts were starved overnight in DMEM. In Stat6 reconstitution experiments, SV40 immortalized wild-type or Stat6 7/7 ®broblasts were substituted. Cells were treated for 20 min with 100 ng/ml PDGF BB. Cells were washed once with PBS, 100 mM sodium orthovanadate and solubilized in gel shift lysis buer (50 mM Tris pH 8.0, 0.5% Nonidet P40, 10% glycerol, 100 mM EDTA, 50 mM NaF, 167 mM NaCl, 100 mM sodium orthovanadate, 1 mM dithiotheitol, 400 mM phenylmethylsulfonyl¯uoride, 1.5 mg/ml aprotinin, 1 mg/ml leupeptin, 1 mg/ml pepstatin) by incubation on ice for 60 min and vortexing 3 ± 5 times. Lysates were cleared by centrifugation at 14 000 r.p.m. for 10 min. Protein concentrations were determined by the method of Bradford.
For EMSA, 5 mg of whole cell lysate was incubated with the [
32 P]oligonucleotide ([ 32 P]Ie) probe in 20 mM HEPES (N-2-Hydroxyethylpiperazine-N'-2-Ethanesulfonic Acid) pH 7.9, 40 mM KCl, 1 mM MgCl 2 , 100 mM EDTA, 500 mM dithiothreitol, 6.0% glycerol, 1 mg/ml bovine serum albumin, and 100 mg/ml poly dIdC for 15 min, then fractionated on 0.226TBE (100 mM Tris borate pH 8.0, 2 mM EDTA), 4.5% acrylamide gels. The sequence of one strand of the double stranded Ie used for EMSA was 5'-GATC-TAACTTCCCAAGAACAG-3'.
Mitogenic assay
Early passage ®broblast [
3 H]thymidine incorporation was measured as previously described (LaRochelle et al., 1989) with the following modi®cations. Brie¯y, quiescent ®broblasts in 96 well microtiter plates were treated with the indicated concentrations of PDGF BB in the presence or absence of 1 mg/ml murine IL-4. Cells were incubated at 378C for 16 h. [ 3 H]thymidine (5 mCi/ml) was then added for 5 h. Cells were washed, harvested, and [ 3 H]thymidine uptake was quantitated using a Beckman 5500 scintillation counter.
IL-6 and MCP-1 two-site assay and Northern blot analysis IL-6 and MCP-1 were detected by two-site assay kits utilized according to manufacturer's speci®cations (R&D Systems, Minneapolis, MN, USA). For Northern blot analysis, total RNA was prepared from ®broblasts in the presence of TriZol (Gibco/BRL Inc., Gaithersburg, MD, USA), extracted with chloroform, and recovered by precipitation with cold isopropanol. Typically, 20 mg of total RNA was resolved by electrophoresis on 1.4% formaldehyde agarose gels and transferred to Nytran nylon membranes. After crosslinking of the RNA to the membrane, ®lters were prehybridized for 2 h at 428C in Hybrisol-I (Oncor, Gaithersburg, MD, USA) (50% formamide, 10% dextran sulphate, 1% SDS, 66SSC and blocking agents) and then hybridized for 20 h in the same solution containing a 32 P-labeled probe corresponding to a 600 bp BglII/XhoI fragment of the mouse IL-6 cDNA or a 2.7 Kbp EcoRI/BamHI fragment of the human MCP-1 cDNA. Filters were washed twice (30 min each) at room temperature in 26SSC-0.1% SDS and twice at 508C in 0.16SSC-0.1% SDS and exposed to Kodak XAR ®lm. Induction was quantitated using the program NIH Image 1.61.
